The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict STAAR Surgical's revenues will increase 7.2% and EPS will contract 0.0%.
The average estimate for revenue is $17.6 million. On the bottom line, the average EPS estimate is $0.03.
Last quarter, STAAR Surgical chalked up revenue of $15.9 million. GAAP reported sales were 3.9% higher than the prior-year quarter's $15.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.04. GAAP EPS of $0.00 were the same as the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 70.4%, 190 basis points better than the prior-year quarter. Operating margin was 4.0%, 80 basis points worse than the prior-year quarter. Net margin was -0.6%, 110 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $64.9 million. The average EPS estimate is $0.09.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 80 members out of 88 rating the stock outperform, and eight members rating it underperform. Among 27 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 21 give STAAR Surgical a green thumbs-up, and six give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on STAAR Surgical is outperform, with an average price target of $9.65.
Is STAAR Surgical the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add STAAR Surgical to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
5 of Last Week's Biggest Losers
These five stocks suffered double-digit percentage declines last week.
3 Stocks Crushed by the Market This Week
No pops and sizzles for these stocks. Just drops and fizzles.
Why STAAR Surgical Company Shares Are Seeing Big Gains
STAAR Surgical surges after a positive FDA panel review. Can shares head even higher?